E
89.19
-0.90 (-1.00%)
| 前收盘价格 | 90.09 |
| 收盘价格 | 90.11 |
| 成交量 | 533,461 |
| 平均成交量 (3个月) | 3,552,982 |
| 市值 | 51,409,117,184 |
| 市盈率 (P/E TTM) | 53.09 |
| 预期市盈率 (P/E Forward) | 25.64 |
| 价格/销量 (P/S) | 7.75 |
| 股市价格/股市净资产 (P/B) | 4.71 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | 75.71% |
| 营业利益率 (TTM) | 29.01% |
| 稀释每股收益 (EPS TTM) | 2.42 |
| 季度收入增长率 (YOY) | 6.20% |
| 季度盈利增长率 (YOY) | 1.70% |
| 总债务/股东权益 (D/E MRQ) | 6.86% |
| 流动比率 (MRQ) | 4.45 |
| 营业现金流 (OCF TTM) | 876.20 M |
| 杠杆自由现金流 (LFCF TTM) | 1.45 B |
| 资产报酬率 (ROA TTM) | 8.42% |
| 股东权益报酬率 (ROE TTM) | 16.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Edwards Lifesciences Corporatio | 混合的 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 4.0 |
| 相对估值 | -5.0 |
| 财务健康 | 5.0 |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| 平均 | 0.75 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.91% |
| 机构持股比例 | 89.29% |
该时间范围内无数据。
该时间范围内无数据。
投资组合